MX2022002324A - Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos. - Google Patents
Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos.Info
- Publication number
- MX2022002324A MX2022002324A MX2022002324A MX2022002324A MX2022002324A MX 2022002324 A MX2022002324 A MX 2022002324A MX 2022002324 A MX2022002324 A MX 2022002324A MX 2022002324 A MX2022002324 A MX 2022002324A MX 2022002324 A MX2022002324 A MX 2022002324A
- Authority
- MX
- Mexico
- Prior art keywords
- hybridoma
- developing
- platform
- efficient
- therapeutic antibody
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/166—Animal cells resulting from interspecies fusion
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente tecnología generalmente se refiere a los procedimientos mejorados para producir anticuerpos, colecciones de anticuerpos, hibridomas, colecciones de hibridomas, etc. Por ejemplo, estos procedimientos incrementan la cantidad de linfocitos B específicos al antígeno producidos, incrementan la cantidad de hibridomas y/o incrementan la cantidad de anticuerpos monoclonales que se pueden producir en un ciclo de producción dado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962894660P | 2019-08-30 | 2019-08-30 | |
PCT/US2020/048440 WO2021041834A1 (en) | 2019-08-30 | 2020-08-28 | Developing an efficient hybridoma platform for therapeutic antibody discovery |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002324A true MX2022002324A (es) | 2022-04-06 |
Family
ID=74686058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002324A MX2022002324A (es) | 2019-08-30 | 2020-08-28 | Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220177551A1 (es) |
EP (1) | EP4021489A4 (es) |
JP (1) | JP2022546412A (es) |
KR (1) | KR20220053596A (es) |
CN (1) | CN114340660A (es) |
AR (1) | AR119866A1 (es) |
AU (1) | AU2020336473A1 (es) |
BR (1) | BR112022003170A2 (es) |
CA (1) | CA3148521A1 (es) |
IL (1) | IL290937A (es) |
MX (1) | MX2022002324A (es) |
TW (1) | TW202122107A (es) |
WO (1) | WO2021041834A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117120468A (zh) * | 2021-02-05 | 2023-11-24 | 美国安进公司 | 增强的杂交瘤生成 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007003041A1 (en) * | 2005-07-01 | 2007-01-11 | John Schrader | Methods of isolating cells and generating monoclonal antibodies |
EP2027158B1 (en) * | 2006-05-02 | 2012-09-19 | Carviar ApS | Method for immunizing an avian species |
WO2011146514A2 (en) * | 2010-05-17 | 2011-11-24 | The Board Of Regents Of The University Of Texas System | Rapid isolation of monoclonal antibodies from animals |
DK3218406T3 (da) * | 2014-11-10 | 2021-06-21 | Medimmune Ltd | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf |
-
2020
- 2020-08-28 AU AU2020336473A patent/AU2020336473A1/en active Pending
- 2020-08-28 WO PCT/US2020/048440 patent/WO2021041834A1/en active Application Filing
- 2020-08-28 JP JP2022513161A patent/JP2022546412A/ja active Pending
- 2020-08-28 KR KR1020227007942A patent/KR20220053596A/ko unknown
- 2020-08-28 MX MX2022002324A patent/MX2022002324A/es unknown
- 2020-08-28 CA CA3148521A patent/CA3148521A1/en active Pending
- 2020-08-28 CN CN202080061072.0A patent/CN114340660A/zh active Pending
- 2020-08-28 AR ARP200102434A patent/AR119866A1/es unknown
- 2020-08-28 EP EP20858144.7A patent/EP4021489A4/en active Pending
- 2020-08-28 TW TW109129578A patent/TW202122107A/zh unknown
- 2020-08-28 BR BR112022003170A patent/BR112022003170A2/pt unknown
-
2022
- 2022-02-25 US US17/681,665 patent/US20220177551A1/en active Pending
- 2022-02-27 IL IL290937A patent/IL290937A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202122107A (zh) | 2021-06-16 |
JP2022546412A (ja) | 2022-11-04 |
BR112022003170A2 (pt) | 2022-05-17 |
EP4021489A1 (en) | 2022-07-06 |
EP4021489A4 (en) | 2023-10-11 |
IL290937A (en) | 2022-04-01 |
AU2020336473A1 (en) | 2022-03-03 |
AR119866A1 (es) | 2022-01-19 |
KR20220053596A (ko) | 2022-04-29 |
CN114340660A (zh) | 2022-04-12 |
WO2021041834A1 (en) | 2021-03-04 |
CA3148521A1 (en) | 2021-03-04 |
US20220177551A1 (en) | 2022-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ728874A (en) | Anti-pd-1 monoclonal antibody and obtaining method therefor | |
JOP20190283A1 (ar) | طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها | |
DK1414858T3 (da) | Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf | |
MX2024000317A (es) | Anticuerpos biespecificos contra calicreina y factor xii del plasma. | |
MX344595B (es) | Humanizacion rapida de anticuerpos. | |
ZA202001114B (en) | Dynamic human heavy chain antibody libraries | |
NZ592036A (en) | Methods for producing antibodies from plasma cells | |
MX2021014973A (es) | Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. | |
PH12019501089A1 (en) | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same | |
JOP20210286A1 (ar) | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr | |
AU2017428934A8 (en) | Dynamic human antibody light chain libraries | |
MX2022002324A (es) | Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos. | |
ZA202203622B (en) | Anti-cd47 monoclonal antibody and use thereof | |
MX2021012767A (es) | Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3. | |
ZA202208337B (en) | A bispecific anti-pd-l1/vegf antibody and uses thereof | |
MX2021012765A (es) | Metodos para tratar el cancer renal con un anticuerpo anti-psma/cd3. | |
MX2022003833A (es) | Anticuerpos anti-kir3dl3 y sus usos. | |
ATE370163T1 (de) | Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen | |
CR20220061A (es) | Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células | |
ZA202305072B (en) | Cd1a antibodies and uses thereof | |
MX2023010687A (es) | Anticuerpos monoclonales anti cd47 y usos de los mismos. | |
WO2012104014A8 (en) | A method for the production of hybridoma cell lines producing monoclonal antibodies capable to specifically binding to a human c44-fragment of agrin | |
EP3778645A4 (en) | MONOCLONAL ANTIBODIES SPECIFICALLY RESPONDING TO NCC-ST-439 ANTIGEN AND METHOD FOR MANUFACTURING IT | |
EA202091053A1 (ru) | Модифицированные c- и ch1-домены | |
HK1245303A1 (zh) | 生產抗原特異性b細胞的方法及其用於生產雜交瘤細胞和單克隆抗體 |